Skip to main content

Health condition · Clinically reviewed

Lobular carcinoma in situ, a risk marker, not a cancer diagnosis.

LCIS is usually found by chance on a biopsy taken for something else. It signals higher future risk in both breasts - and the right response depends on which type you have.

Jump to treatment
A radiographer guides a patient onto the bed of an advanced 3 Tesla MRI scanner in a London imaging suite

Why trust this guide

  • 01

    Clinically reviewed

    Written by our editorial team and reviewed by a registered UK clinician before publication.

  • 02

    Sourced from guidance

    Checked against NICE, the Association of Breast Surgery and peer-reviewed sources you can see at the end.

  • 03

    Current for 2026

    Reflects modern UK guidance on classic versus pleomorphic LCIS, surveillance and risk-reduction options.

Key facts

LCIS at a glance.

The essentials, in plain English - what it is, why it differs from DCIS, and how it’s managed in the UK today.

  • What it is

    A non-invasive proliferation of abnormal cells within the breast lobules, with loss of E-cadherin - the feature that separates it from DCIS.

  • Risk marker, not a precursor

    LCIS is treated as a marker of raised future breast cancer risk in either breast, rather than a direct step towards invasive disease.

  • Usually incidental

    Rarely causes a lump or a mammographic abnormality itself - most often found on a core biopsy taken for another reason, such as calcification.

  • Two patterns

    Classic LCIS is usually low risk and often managed with surveillance. Pleomorphic LCIS is a more aggressive variant that usually needs excision.

  • Excision after biopsy

    Diagnosis on core biopsy often prompts surgical excision to exclude co-existing invasive cancer, particularly for the pleomorphic type.

  • Risk reduction

    Enhanced surveillance, chemoprevention and, rarely, risk-reducing mastectomy are the main long-term options, chosen with shared decision-making.

Why this guide matters

The type of LCIS changes everything.

LCIS is often misunderstood as a small cancer. It isn’t - and the distinction between classic and pleomorphic disease drives the whole plan below.

  • A risk marker, not a precursor

    Unlike DCIS, LCIS is not treated as a direct step towards invasive cancer - it signals raised future risk in either breast.

  • Classic and pleomorphic differ

    Classic LCIS is often watched with surveillance alone. Pleomorphic LCIS behaves more aggressively and is usually excised.

  • Risk reduction is a long game

    Surveillance, chemoprevention and lifestyle measures work together over years, not weeks - and the plan can change as your risk profile does.

How the diagnosis is made

From an incidental finding to a clear plan.

The steps a UK breast unit will normally follow, in order - so you know what to expect and why.

  1. 01

    Assessing

    Incidental finding on biopsy

    LCIS is usually spotted on a core biopsy taken because of calcification or another lesion seen on mammography, not because of a symptom.

  2. 02

    Assessing

    Pathology review

    A specialist breast pathologist confirms the diagnosis and, crucially, distinguishes classic LCIS from the pleomorphic variant.

  3. 03

    Assessing

    Radiology correlation

    The biopsy result is checked against the mammogram or ultrasound appearance - concordance assessment - to make sure the sampled area explains the imaging finding.

  4. 04

    Confirming

    MDT discussion

    A specialist breast multidisciplinary team weighs the pathology, imaging and patient factors to agree a management plan.

  5. 05

    Confirming

    Excision if indicated

    For pleomorphic LCIS, or where imaging and pathology do not fully match, surgical excision is arranged to exclude co-existing invasive or in-situ cancer.

  6. 06

    Preparing

    MRI breast if extent unclear

    Breast MRI is used selectively, in specialist commissioned services, to map extent when it will change the surgical or surveillance plan.

  7. 07

    Preparing

    Risk assessment and planning

    Family history, genetic risk and personal preference feed into a long-term plan of surveillance, chemoprevention or, rarely, risk-reducing surgery.

Typical timeline: biopsy to an agreed plan in a few weeks, through your specialist breast MDT.

Features

What LCIS actually looks like.

Usually silent, usually incidental - and the pathology features that separate classic disease from the pleomorphic variant.

  • No lump to feel

    Classic LCIS very rarely produces a palpable mass - it is usually silent on examination.

  • No mammographic signature of its own

    It does not typically create its own calcification or density - it is found alongside another lesion being biopsied.

  • Loss of E-cadherin

    The defining pathology feature - contrast with DCIS, which keeps normal E-cadherin expression on the cell surface.

  • Bilateral risk

    LCIS raises the future breast cancer risk in both breasts, not just the one it was found in.

  • Pleomorphic variant

    Larger, more atypical cells with a higher chance of coexisting invasive disease - a stronger case for excision.

  • Often multifocal

    LCIS frequently affects several lobules across an area of breast tissue, sometimes discovered at more than one site.

  • Age at diagnosis

    Most often diagnosed around or after the menopause, though it can be found at any adult age on screening or diagnostic biopsy.

  • Red flag - a new lump or discharge

    A palpable lump, skin change or nipple discharge is not typical of LCIS and needs prompt reassessment for invasive disease.

Treatment

How LCIS is managed in the UK.

Surveillance for classic disease, excision for pleomorphic disease - and a long-term menu of risk-reduction options for everyone.

  • Surveillance (classic LCIS)

    For classic LCIS that is concordant with imaging, many specialist centres now manage it with observation alone rather than routine excision.

  • Excision (pleomorphic LCIS)

    Pleomorphic LCIS carries higher-risk features and is usually removed surgically to exclude coexisting invasive or in-situ disease.

  • Enhanced surveillance

    Annual mammography, with MRI in selected cases, keeps close watch on both breasts given the bilateral risk that LCIS represents.

  • Chemoprevention

    Tamoxifen or anastrozole can meaningfully lower future breast cancer risk in selected patients, agreed through a specialist risk clinic.

  • Risk-reducing mastectomy

    Reserved for a small number of very high-risk patients, usually where LCIS sits alongside a strong family history or a BRCA mutation.

  • Lifestyle risk reduction

    Maintaining a healthy weight, limiting alcohol and staying active all contribute modestly but meaningfully to lowering breast cancer risk.

  • Genetic counselling

    Offered where family history suggests an inherited predisposition, to guide testing and inform the surveillance or prevention plan.

  • MDT-led shared decision-making

    Every option above is discussed through a specialist breast multidisciplinary team, with the final plan agreed together with the patient.

What this guide is based on

The sources behind every claim on this page.

UK national guidance and specialist society standards, current at the time of last review.

Key references

Guidelines and standards we relied on.

A quiet reminder

This guide is for information, not medical advice.

Your breast specialist knows your pathology, imaging and history, and can tell you which parts apply to you. If in doubt, get seen.

  • NICE. Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer (CG164).

  • Association of Breast Surgery (ABS). Guidance on the management of lobular neoplasia diagnosed on core biopsy.

  • Royal College of Pathologists. Dataset for histopathological reporting of breast disease.

  • Breast Cancer Now. Information on lobular carcinoma in situ and breast cancer risk.

Red flags

When LCIS needs urgent attention.

Most LCIS is safely watched or excised on a planned basis. These are the situations that need a faster response.

  • New palpable lump

    A lump that can be felt is not typical of LCIS and should prompt urgent reassessment to exclude invasive cancer.

  • Skin or nipple change

    Skin dimpling, nipple inversion or nipple discharge are not features of LCIS and need prompt clinical review.

  • Upgrade on excision

    Excision occasionally reveals invasive or in-situ cancer not seen on the original core biopsy - this changes the treatment pathway.

  • Pleomorphic LCIS left unexcised

    This more aggressive variant carries a meaningfully higher chance of coexisting invasive disease if surveillance is chosen instead of excision.

  • Strong family history or BRCA

    LCIS alongside a strong family history or a known BRCA mutation substantially raises lifetime risk and warrants genetics input.

  • Discordant imaging and pathology

    When the biopsy result does not match the mammogram or ultrasound appearance, further sampling or excision is usually needed.

  • Interval symptoms between scans

    Any new symptom between planned surveillance appointments should be assessed promptly rather than waiting for the next scheduled scan.

  • Non-adherence to chemoprevention monitoring

    Tamoxifen and anastrozole need periodic review for side effects - missed monitoring should be flagged to the specialist team.

  • Contralateral change

    Because LCIS raises risk in both breasts, a new finding in the opposite breast needs the same careful work-up as the original side.

Living with it

A manageable risk, with a clear plan.

Four things that make the biggest difference after an LCIS diagnosis - understanding what it means, keeping appointments, weighing chemoprevention, and knowing where to find support.

A quiet reminder

Raised risk is not the same as disease.

A well-run surveillance plan, kept up year after year, is how most people with LCIS stay ahead of any change.

  1. 01 Understand

    A risk marker, not a cancer diagnosis

    LCIS means your future risk is higher - it does not mean you have cancer now. That distinction shapes every decision that follows.

  2. 02 Attend

    Keep every surveillance appointment

    Annual mammography, and MRI where advised, is how classic LCIS is safely watched without surgery for most people.

  3. 03 Discuss

    Ask about chemoprevention

    Tamoxifen or anastrozole are not right for everyone, but they are worth an open conversation with your specialist team.

  4. 04 Support

    Lean on specialist support

    Breast Cancer Now and your breast care team can help with the emotional side of living with raised risk, not just the medical side.

Frequently asked

Everything we get asked about LCIS.

Quick answers on classic versus pleomorphic disease, surveillance, excision and risk reduction.

  • What is lobular carcinoma in situ (LCIS)?

    LCIS is a non-invasive growth of abnormal cells within the breast lobules, marked by loss of E-cadherin on the cell surface. Unlike DCIS, which is considered a direct precursor to invasive cancer, LCIS is treated as a risk marker for future breast cancer in either breast.

  • Is LCIS the same as breast cancer?

    No. LCIS is not cancer itself - it is a non-invasive finding that raises the likelihood of developing breast cancer later, in either breast. It is usually found incidentally on a biopsy taken for another reason.

  • How is classic LCIS different from pleomorphic LCIS?

    Classic LCIS involves smaller, more uniform cells and is generally lower risk, often managed with surveillance alone. Pleomorphic LCIS has larger, more atypical cells and behaves more aggressively, so excision is usually recommended to exclude coexisting invasive disease.

  • Will I need surgery if I am diagnosed with LCIS?

    Not necessarily. Many centres now manage classic LCIS with surveillance alone if it is concordant with imaging. Pleomorphic LCIS, or any case with discordant imaging, is more likely to need surgical excision.

  • Does LCIS mean I will get breast cancer?

    No - it means your lifetime risk is higher than average, not that cancer is inevitable. Many people with LCIS never develop invasive breast cancer, particularly with regular surveillance and, where appropriate, risk-reducing measures.

  • What can I do to reduce my risk after an LCIS diagnosis?

    Options include enhanced surveillance with annual mammography, chemoprevention with tamoxifen or anastrozole, lifestyle measures such as maintaining a healthy weight and limiting alcohol, and, rarely, risk-reducing mastectomy for those at very high risk. Your specialist team will help you choose what fits your circumstances.

Related content

Keep reading.

Pulse Healthcare concierge

Send us your enquiry

A concierge service for UK private healthcare. We match you with the best vetted clinics and consultants in our network - they then contact you directly.

So we can match you to the right clinician close to you.

We reply to every enquiry within 24 hours (Mon–Fri). Confidential - your details are never shared outside our vetted consultant network.